Supriya Lifescience Receives US FDA EIR with VAI Status for Lote Parshuram Facility
Supriya Lifescience receives US FDA EIR with VAI classification for its Lote Parshuram facility, closing the February 2026 audit inspection cycle.
USFDA Form 483 Observation | 23/04/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy